Brief: Voyager Enters Into License For Next-Generation Capsid, Bringing Partnered Portfolio Of Tracer-Enabled Gene Therapies To 14
Novartis AG NOVN.S :
* VOYAGER ENTERS INTO LICENSE FOR NEXT-GENERATION CAPSID,
BRINGING
PARTNERED PORTFOLIO OF TRACER-ENABLED GENE THERAPIES TO 14
* VOYAGER THERAPEUTICS: TO GET $15M UPFRONT, ELIGIBLE TO GET
UP TO
$305 MILLION IN ASSOCIATED MILESTONE PAYMENTS
Source text for Eikon: ID:nGNXbWxl31
Further company coverage: NOVN.S
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview